- Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL)
-
Jun-Ho Lee
-
Yeungnam Univ J Med. 2021;38(3):175-182. Published online January 19, 2021
-
DOI: https://doi.org/10.12701/yujm.2020.00801
-
-
5,781
View
-
162
Download
-
1
Citations
-
 Abstract
 PDF
- Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare T-cell non-Hodgkin lymphoma characterized as CD30 positive and anaplastic lymphoma kinase (ALK) negative. In 2016, the World Health Organization declared BIA-ALCL as a new disease entity. The first case of BIA-ALCL was reported in 1997, and as of July 2019, the United States Food and Drug Administration had cited a total of 573 United States and global medical device reports of BIA-ALCL, including 33 deaths. In all clinical case reports, except for those with unknown clinical history, the patient had received at least one textured surface breast implant. Although the etiology is not yet clear, chronic inflammation has been proposed as a potential precursor to tumorigenesis. The most common presentation of BIA-ALCL is peri-implant fluid collection following aesthetic or reconstructive implantation with textured surface breast implants. It can be accompanied by breast swelling, asymmetry, pain, skin lesions, lymphadenopathy, and B-type symptoms. Most cases are detected on average 7 to 10 years after implantation. Diagnostic specimens can be obtained with fine-needle aspiration or biopsy. BIA-ALCL is CD30 positive, epithelial membrane antigen positive, and ALK negative. It can be cured with complete surgical excision at the T1–T3 stage.
-
Citations
Citations to this article as recorded by  - Comprehensive Evaluation of the Current Knowledge on Breast Implant Associated-Anaplastic Large Cell Lymphoma
Hyokyung Yoo, Ji-Ung Park, Hak Chang
Archives of Plastic Surgery.2022; 49(02): 141. CrossRef
|
E-Submission
Yeungnam University College of Medicine
